Cancer Research Studies
Treatment: Lung Cancer
Study Title:
MAGRIT 109493: A double-blind, randomized,
placebo-controlled Phase III study to assess the efficacy of recMAGE-A3
+ AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in
patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer
Study Title:
ECOG 1505 A Phase III Randomized Trial of Adjuvant Chemotherapy with
or without Bevacizumab for Patients with Completely Resected Stage 1B-IIIA
Non-Small Cell Cancer (NSCLC).
Study Title:
MAGRIT 109493: A double-blind, randomized, placebo-controlled Phase III study
to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic
as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small
Cell Lung Cancer
What is the purpose of this study?
The purpose of this study is to determine whether adding a vaccine
to boost immune response in conjunction with chemotherapy and surgery
will prove to be clinically effective (resulting in disease free survival)
in patients diagnosed with lung cancer.
Am I a candidate for this study?
- Do you have a stage IB through IIIA lung cancer that has been surgically
removed?
- Can you perform most or all of your activities of daily living?
What do I have to do?
- Agree to have a sample of lung tissue tested for a particular protein.
If your tissue is positive you may be eligible for the study.
- Agree to have blood drawn.
- Agree to undergo CT scan every 6 months, periodic chest x-rays, and
physical exams.
- Receive a vaccine several times throughout the study.
- Agree to be contacted by the research staff for up to 5 years after
beginning the study.
Why should I participate?
- Currently, chemotherapy is the standard treatment for stage II
and III lung cancers.
- Many patients receiving chemotherapy will relapse.
- There is a medical need for additional treatments for stage IB to
IIIA lung cancers.
- This vaccine has demonstrated effectiveness in earlier studies and
may prolong disease free survival.
If you are interested in participating in this
lung cancer research study, please contact:
Kristin Sorensen, MS, RN, clinical research nurse
sorenk@holycrosshealth.org
301.754.7961
Principle Investigator: Kashif Firozvi, MD, medical
oncologist
Co-investigator: Lawrence Markovitz, MD thoracic surgeon
Study Title:
ECOG 1505 A Phase III Randomized Trial of Adjuvant Chemotherapy with
or without Bevacizumab for Patients with Completely Resected Stage
1B-IIIA Non-Small Cell Cancer (NSCLC).
What is the purpose of this study?
The purpose of this study is to determine
if adding the new drug bevacizumab to standard chemotherapy improves
the chances for cure for patients who have had surgery.
Am I a candidate
for this trial?
In order to be a candidate for this trial:
- You
must be at least 18 years of age.
- You must have undergone
a complete resection of your lung cancer.
- You must have
a diagnosis of stage 1B-IIIA non-small cell lung cancer.
- You
must not have received any prior chemotherapy or hormonal cancer
therapy or radiation therapy within the past five years.
- You
must not have health history problem related to bleeding or blood
clotting or have a history of stroke or TIAs.
Why should I participate?
Your participation in this study may help cancer researchers determine
if this new drug, bevacizumab, improves the chance for longer survival
or a cure for patients who have had their lung cancer removed by
surgery.
- What do I need to do?
Most importantly,
you will need to agree to meet with a member of the research team
to learn all the details about this study and your possible participation.
- Agree to be randomized into one of two treatment
groups.
- Agree
to be treatment for possibly up to a year.
- You will
need to agree to allow the research staff to gather information on
your health for 10 years.
- Agree to participate in a smoking
status survey.
If you are interested in this lung cancer research
study, please contact: Lyudmila Kalnitskaya, study coordinator, kalnitl@holycrosshealth.org at 301.754.7961.
Principle Investigator: Dr. Kashif Firozvi,
MD, medical oncologist
Return to top.